Report overview
The global Cancer Minimal Residual Disease Testing market was valued at 1007 million in 2024 and is projected to reach US$ 1659 million by 2032, at a CAGR of 7.6% during the forecast period.
Minimal residual disease (MRD) is�a term used to describe the small number of cancer cells in the body after cancer treatment. An MRD positive test result means that disease was still detected after treatment. An MRD negative result means that no disease was detected after treatment.
The market for cancer MRD testing is likely to grow as precision medicine and personalized treatment approaches become more prominent in cancer care. MRD testing can play a significant role in tailoring treatment plans to individual patients.
We have surveyed the Cancer Minimal Residual Disease Testing manufacturers, suppliers, distributors, and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks
This report aims to provide a comprehensive presentation of the global market for Cancer Minimal Residual Disease Testing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cancer Minimal Residual Disease Testing. This report contains market size and forecasts of Cancer Minimal Residual Disease Testing in global, including the following market information:
Global Cancer Minimal Residual Disease Testing market revenue, 2020-2025, 2026-2032, ($ millions)
Global Cancer Minimal Residual Disease Testing market sales, 2020-2025, 2026-2032, (K Units)
Global top five Cancer Minimal Residual Disease Testing companies in 2024 (%)
Total Market by Segment:
Global Cancer Minimal Residual Disease Testing market, by Type, 2020-2025, 2026-2032 ($ millions) & (K Units)
Global Cancer Minimal Residual Disease Testing market segment percentages, by Type, 2024 (%)
Flow Cytometry
Polymerase Chain Reaction (PCR)
Next-Generation Sequencing (NGS)
Other
Global Cancer Minimal Residual Disease Testing market, by Application, 2020-2025, 2026-2032 ($ Millions) & (K Units)
Global Cancer Minimal Residual Disease Testing market segment percentages, by Application, 2024 (%)
Hematological Malignancies
Leukemia
Lymphoma
Solid Tumors
Other
Global Cancer Minimal Residual Disease Testing market, by region and country, 2020-2025, 2026-2032 ($ millions) & (K Units)
Global Cancer Minimal Residual Disease Testing market segment percentages, by region and country, 2024 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Cancer Minimal Residual Disease Testing revenues in global market, 2020-2025 (estimated), ($ millions)
Key companies Cancer Minimal Residual Disease Testing revenues share in global market, 2024 (%)
Key companies Cancer Minimal Residual Disease Testing sales in global market, 2020-2025 (estimated), (K Units)
Key companies Cancer Minimal Residual Disease Testing sales share in global market, 2024 (%)
Further, the report presents profiles of competitors in the market, key players include:
Adaptive Biotechnologies Corporation
ArcherDX, Inc. (Invitae Corporation)
Asuragen
Arup Laboratories
Bio-Rad Laboratories
Cergentis B.V.
F. Hoffmann- La Roche Ltd
Guardant Health
ICON plc
Invivoscribe
Laboratory Corporation of America Holdings
Mission Bio
Natera, Inc.
NeoGenomics Laboratories
Opko Health
Quest Diagnostics Incorporated
Sysmex Corporation
Genetron Health
Outline of Major Chapters:
Chapter 1: Introduces the definition of Cancer Minimal Residual Disease Testing, market overview.
Chapter 2: Global Cancer Minimal Residual Disease Testing market size in revenue and volume.
Chapter 3: Detailed analysis of Cancer Minimal Residual Disease Testing manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Cancer Minimal Residual Disease Testing in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Cancer Minimal Residual Disease Testing capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
